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Background:  Studies of Pediatric Liver Transplantation (SPLIT) was founded in 1995 in order to collect 
comprehensive prospective data on pediatric liver transplantation, including waiting list data, transplant, and early 
and late outcomes.   Since 2011, data collection of the current registry has been refined to focus on prospective 
data and outcomes only after transplant to serve as a foundation for the future development of targeted clinical 
studies.
Objective: To report the outcomes of the SPLIT registry from 2011-2018
Methods:  This is a multicenter, cross-sectional analysis characterizing patients transplanted and enrolled in the 
SPLIT registry between 2011-2018. All patients, <18 years of age, who received a first liver-only, a combined liver-
kidney, or a combined liver-pancreas transplant during this study period.  
Results: 1911 recipients from 39 participating centers in North America were registered.. Indications included 
biliary atresia (38.5%), metabolic disease (19.1%), tumors (11.7%), and fulminant liver failure (11.5%). Greater than 
50% of recipients were transplanted as either Status 1A/1B or with a MELD/PELD exception score. Incompatible 
transplants were performed in 4.1%.  Kaplan Meier estimates of 1 year patient and graft survival were 97.3% and 
96.6%.
First 30 days surgical complications included reoperation (31.7%), hepatic artery thrombosis (6.3%), and portal vein 
thrombosis (3.2%). In the first 90 days, biliary tract complications were reported in 13.6%. Acute cellular rejection 
during first year was 34.7%. At 1 and 2 year follow-up, 39.2% and 50.6% had normal liver tests on monotherapy 






In 1995, the Studies of Pediatric Liver Transplantation (SPLIT) was designed as a multi-center, observational, 
longitudinal registry to collect prospective data on children receiving liver transplantation in the United States and 
Canada. It was specifically formed to help characterize patient outcomes before and after liver transplant.  This 
registry served as the backbone for multiple major collaborative publications on pediatric liver transplantation and 
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Between 1995 and 2009, funding evolved from Industry support to NIH (U01-DK061693-01A1) support. The SPLIT 
registry evolved to maintain its distinctive role in providing long term outcome data at a more granular level than 
that available in other databases. In 2009, the registry came to a cross-road, requiring center-specific support to 
keep SPLIT and the registry moving forward.  Given limited funding, there were strategic discussions to ensure that 
only the most important data be collected to limit the burden on participating centers.  Registry design focused on 
specific participant data that would be needed to help complete our stated goals. In addition, there was a special 
focus on facilitating ancillary studies, with the SPLIT database being able to collect specific supplemental data 
elements for finite periods of time.
After being vetted and refined by participating SPLIT investigators, the updated registry began enrolling new 
transplant recipients in 2011.  In addition, sites attempted to re-consent patients already followed in SPLIT before 
2009 in order to collect their long-term data from 2011 onwards. The stated goal of this new registry was to 
improve outcomes in children receiving liver transplants by collecting specific data that could serve as a foundation 
for the development of targeted clinical studies.7  Since 2011, the specific aims of the SPLIT registry are to collect 
prospective data to identify opportunities to improve 30 day and 90 day outcomes and prospectively collect data 
from pediatric liver transplant survivors more than one year after transplant so as to identify emerging outcomes, 
clarify predictors for these outcomes and identify best practice. As part of this rejuvenated effort, the SPLIT 
Registry Committee oversaw the revision of a refined and streamlined database, ably managed by the same data 
coordinating center, Emmes. As part of this effort, Emmes generated improved static center specific outcomes 
reports that centers could access via web-based entry, with up-to-the-day information. In addition, the new 
registry has allowed for SPLIT, guided by our QI committee, to develop a web-based interactive benchmarking 
application. Centers are now able to ascertain specific outcome measures (graft/patient survival, rejection, 
vascular/biliary complications, reoperation, infection) as a function of customizable transplant variables (diagnosis, 
donor type, procedure type, recipient size, age, and transplant year) to benchmark their outcomes against the 
cohort of participating SPLIT centers in a more meaningful and fluid manner.
This report aims to describe the most current information about the new SPLIT registry population from 2011 to 
March 2018, highlighting areas of opportunity for ongoing investigation.
Patients and Methods
Inclusion criteria were all patients, less than 18 years of age, who received a first liver-only, a combined liver-
kidney, or a combined liver-pancreas transplant at a participating SPLIT center.  Exclusion criteria were other 
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and/or research ethics board (REB) approval for data collection and analysis. Individual informed consent was 
obtained from parents and/or guardians.
Data were submitted to the Data Coordinating Center, Emmes, through a secure internet portal at specific time 
points including: at first transplant, 30 day follow-up, 90 day follow-up, 1 year follow-up, and annually thereafter. If 
patients have graft failure requiring re-transplant, data were collected at the same time points for the new graft.   
Participants could be withdrawn from the study for any of the following reasons: receiving a bone marrow 
transplant, death, transferring care to a non-SPLIT center, transferring to an adult provider or deciding to 
terminate participation by the participant, guardian or investigator. 
Data collected included patient demographics, donor characteristics, transplant surgery details, patient survival, 
graft survival, allograft function, immunosuppression, concomitant medications, rejection episodes, growth trends, 
early complications (readmissions, reoperations, infections, cancer, and laboratory assessments), late 
complications, blood pressure trends, laboratory assessments, cancer occurrence, and measures of renal function. 
Statistical analysis
Data are presented as percentage, mean, or median. The Kaplan-Meier method was used for estimating time to 
first rejection, as well as graft and patient survival. Logrank test was used to compare survival outcomes between 
groups.  The non-parametric Kruskal-Wallis test was used to compare the distribution of continuous variables and 
Fisher’s exact test was used to compare event rates between groups.  All statistical analyses were performed using 
the SAS System for Windows version 9.4 (SAS Institute Inc., Cary, NC).  
In addition to the data collected, two separate analyses were performed. The first analysis stratified data by 
program size to determine if program volume affected clinical outcomes. Transplant volume was determined by 
the number of transplants per year reported to UNOS (or reported from Canadian sites) between 2011 and 2017. 
Center size was divided into two groups: <10 or ≥10 pediatric transplants per year. Secondly, to avoid selection 
bias due to underreporting, the investigators defined data quality. The data quality measures chosen were 
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As of March, 2018, the SPLIT registry database contained data on 1911 children who had undergone a first-only 
liver transplant at one of 39 SPLIT centers. Of these enrolled patients, 71 (3.7%) patients required a second liver 
transplant. 
Accessing data from UNOS and Canadian centers, we determined that SPLIT centers transplanted 3002 of 3948 
(76%) of all pediatric liver transplants in the United States and Canada between 2011-2018.  Of these 3002 patients 
that were transplanted at SPLIT centers, 71.3% were enrolled by SPLIT investigators into the registry, representing 
54.2% of all pediatric liver transplants in Canada and United States during the eight years studied. Accrual is shown 
in Figure 1.  
Demographics at first liver transplant
A total of 1911 patients have been enrolled to date. Table 1 summarizes the clinical demographic details of the 
study cohort. Within this group, 28.6% of recipients were less than 1 year of age, and 38.4% were between 1-5 
years of age. Females and males were of equal proportion. The majority of children came from homes with 
married or domestic partnership (71.4%). White race was the majority. 
The primary diagnoses leading to liver transplant are presented in Table 2.  Biliary atresia was the most common 
indication for liver transplantation (38.5%), though less than in previous reports,8 followed by metabolic disease 
(19.1%), tumors (11.7%), and fulminant liver failure (11.5%). (Figure 2)
As for recipient size, 35.1% of children transplanted were less than 10kg, with 2.4% of all recipients being less than 
5kg at the time of transplant.
Organ allocation in the United States is as follows: Status 1A: acute liver failure or hepatic artery thrombosis, 
Status 1B: a)cirrhosis with heavy GI bleeding, intubation, dialysis or coma; b) non-metastatic hepatoblastoma; or c) 
metabolic disease, after spending 30 days on the waitlist with an exception score of PELD/MELD 30. Finally, 
patients on list by MELD/PELD exception or natural score. At the time of transplant, 28.7% of recipients were 
either Status 1A/1B or the medical equivalent in their respective country. Another 29.6% of recipients were 
transplanted with a MELD/PELD exception score. In regards to PELD exception scores, 20% (93/464) were greater 
than 40, 32.5% were between 31-40, 38.1% were between 21-30, and 9% were less than 20.  The majority (51%) of 
MELD exception scores were 30 or greater.
Donor organ type by recipient age is shown in Figure 3. For all transplants, 17.6% received a living donor graft, 
54.4% received a deceased whole liver graft, and 25.2% received a deceased donor technical variant graft.  Of the 
deceased donor technical variant grafts, 34.5% (166/481) were reduced grafts without utilizing the remaining liver 
segments in a second recipient. As recipient age increased, the use of whole grafts increased and technical variants 
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In regards to deceased donor age, over half (57.7%) were from pediatric donors (<18 years of age). Donors less 
than 1 year of age contributed 9.1% of transplant grafts, donors 1-4 years (21.1%), donors 5-17 years (27.5%) and 
donors ≥18 years (33.9%).
Donor-recipient blood type is shown in Table 3.  Donor-recipient blood type match were most commonly identical 
(81.7%), followed by compatible (14.2%), and incompatible (4.1%).  Most common incompatible transplant was 
Donor A/Recipient O (50.7%).  Seventy-five incompatible transplants were performed. Median age at ABO 
incompatible transplant was 10.9 months, (range 0.5 months to 190.7 months). The leading indications for 
transplant in the 75 ABO mismatched recipients were biliary atresia (41.3%), fulminant hepatic failure (17.3%), 
metabolic (10.7%) and tumor (9.3%). Medical status at transplant for this group included 41.3% Status 1A/1B or 
medical equivalent in their country. An additional 38.7% had either an exception score or calculated MELD/PELD ≥ 
25.  
Patient and graft outcomes
In this cross-sectional cohort, 3.8% of participants have died (72/1911). The most commonly reported causes 
(could be multiple causes) were sepsis/infection (11.5%), multi-organ failure (10.8%), malignancy recurrence 
(7.4%), primary respiratory failure (7.3%) and hepatic artery thrombosis (6.1%). Participant Kaplan Meier patient 
survival probability, at 90 days, 1 year, 3 years and 5 years was 98.8%, 97.3%, 95.2%, and 94.2% respectively 
(Figure 4).  Survival probability by center size, (smaller vs. larger) demonstrated no statistical difference when 
analyzed through 3 years (94.7% vs 95.2%). In addition, assessment by data quality compliance showed no 
significant difference at 3 years (95.8% vs 94.6%). 
To date, 7.2% of all grafts reported have been lost secondary to death or re-transplant (137/1911).  Of the patients 
requiring re-transplant, the indication reported was hepatic artery thrombosis (52.3%), other vascular thromboses 
(13.8%), primary graft dysfunction (9.2%), chronic rejection (9.2%), biliary complications (7.7%), hyperacute 
rejection (1.5%), recurrent primary disease (1.5%), other (6.2%).  The probability of first liver transplant graft 
survival recorded at 90 days, 1 year, 3 years and 5 years were 98.4%, 96.6%, 92.2% and 87.7% respectively. Over 
half of these patients have been rescued via re-transplantation (71/137), with 68 having 1 re-transplant, and only 3 
having 2 re-transplants.  Once again, center size comparisons did not reveal statistical significance at similar time 
points. One year graft survival probability (small vs. large) was 92.4% vs 95.1%; 3 years 90.3% vs. 91.9%.  Graft 
survival by data quality compliance was also comparable without statistically significant differences. 
Over the same time period, patients receiving ABO incompatible grafts had worse outcomes than matched or 
compatible grafts (Figure 5). Seven of 75 patients have died (9.3%). The indications for transplant for these 7 
patients included fulminant hepatic failure (3), GALD (1), biliary atresia (1) and tumor (2). The two tumor patients 
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of death.   Graft loss by death or re-transplant for this population was 12/75. After excluding the 7 deaths, the 
other 5 re-transplanted patients had a vascular complication leading to graft loss. These vascular events leading to 
graft loss usually occurred early after transplant.  
Quality measures/Complications
Data points gathered for the purpose of center benchmarking are shown in Table 4. 
Length of intubation was very short; the median days of intubation post-surgery was 1 day (IQR 0, 3). Initial 
hospitalization length of stay for the transplant was a median of 16 days (IQR 11, 27). 
Approximately one-third (31.7%) of patients required a reoperation within the first 30 days, with 71% (431/605) 
having one re-operation.  Most common reasons cited for reoperation (could be multiple reasons) included 
exploratory laparotomy (45.8%), vascular complication (23.2%), biliary tract complication (18%), and intra-
abdominal bleeding (17.5%).  
Vascular and biliary surgical complications are summarized for the entire cohort as well as by center size.  Hepatic 
artery thrombosis was detected in 6.3% of grafts in the first 30 days.   Late hepatic arterial thrombosis (after 90 
days) was rarely reported, with only 0.7% reporting this event.  Portal vein thrombosis was reported in 3.2% of all 
transplants in the first 30 days.  Late portal vein thrombosis (after 90 days) was reported in 1.1% of recipients. 
Biliary tract complications, within the first 90 days, were reported in 13.6% of recipients (250/1844). This included 
biliary leak, biloma, bile duct stricture, or other biliary complication requiring operative repair. 
Culture proven infections including either bacterial, viral or fungal pathogens occurred in 27.6% (502/1911) of 
recipients during the first 30 days after transplant, and 37.9% during the first 90 days.  Of patients having an 
infection, approximately two-thirds were bacterial in nature. Leading types of bacterial infection during the first 30 
days (could be multiple) included intra-abdominal infection (28.6%), blood stream infection (20.2%), urinary tract 
infection (13.9%) and pneumonia (11.7%).  Fungal infections accounted for 15% of all infections and viral infection 
occurred in 37.7% of transplants. 
Re-hospitalization rates, a common QI measure at most transplant centers, have been captured as part of this 
registry. In the first 90 days post-transplant, 44.4% were re-hospitalized. Of the patients re-hospitalized, close to a 
third (28.6%) occurred within 7 days of discharge.  Most common reasons reported for re-hospitalization (could be 
multiple) were fever (30%), abnormal liver tests (16.5%), rejection (11.9%), and fluid-electrolyte imbalance 
(11.1%). An additional 16% were admitted 8-14 days post-discharge, 15.3% 15-30 days post-discharge, and 11.2% 
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Kaplan-Meier probability of being PTLD free over the first two years was calculated. The percentage of patients 
PTLD free at one year was 98.9% and 98.2% at 2 years. 
Further outcome analyses were performed to determine if center size had a significant effect on surgical 
outcomes. There were no statistically significant differences between large and small volume centers for initial 
hospitalization length of stay, reoperation rates, hepatic artery thrombosis or portal vein thrombosis. However, 
there was a statistically significant difference in biliary complications within 90 days, with centers performing less 
than 10 transplants reporting 19.7% in comparison to 11.7% for centers with ≥10 transplants (p<0.001).  Although 
both groups had a median initial intubation of 1 day, using the Kruskal-Wallis test for continuous variables , 
intubation time tended to be longer in the larger centers (p<0.02), but not clinically significant. 
Evaluation for outcomes based on data quality compliance (>80% of UNOS transplants enrolled in SPLIT registry) 
were no statistically different in regards to initial hospitalization length of stay, hepatic artery thrombosis rates 
(5.9% vs 6.8%), or portal vein thrombosis rates (3% vs 3.3%). Reported biliary complications were less in the <80% 
group (11.1% vs 15.1%, p<0.02), and reoperation rates were less in the <80% group (29.3% vs. 33.6%, p<0.02).  
Immunosuppression after first liver transplant 
Figure 6 shows immunosuppression use after first transplant. In comparison to previous SPLIT publications a 
decade ago, tacrolimus has become the primary immunosuppressive agent in 97% percent of recipients after 
transplant. Immunosuppression regimens within 7 days of transplant included Tacrolimus/steroids (57.8%), 
Tacrolimus/antimetabolite/steroids (29%), Tacrolimus/antimetabolite (3.6%), or Tacrolimus alone (5.5%). Of the 39 
SPLIT centers, 29 used antibody induction during this time period.  Antibody induction was used in 32.6% of all 
transplants, with either IL-2 monoclonal antibodies (27.2%) or anti-thymocyte globulin (5%). 
At Day 30 post-transplant, the majority of patients (57.4%) were on dual immunosuppression, with 31.8% 
remaining on triple immunosuppression. Tacrolimus and steroids were the most common immunosuppression 
regimen at 30 days (52.8%).  Antimetabolites were used in 34.3% of patients at the day 30 time point. 
Of the 1448 patients with Year 1 post-transplant immunosuppression data, 55.4% were using a single 
immunosuppressive agent with either tacrolimus or sirolimus; 34.1% were using two immunosuppressive agents 
(Tacrolimus/metabolite or Tacrolimus/steroids), and 9.2% were using three immunosuppressive medications. 
During this first year tacrolimus use decreased to 92.8%, as the use of sirolimus rose to 7.1%.  Anti-metabolites 
were used in 23.2% of recipients at year 1, and 25% of recipients were still taking steroids at this time point.
An additional benchmarking endpoint chosen in the registry was the number of recipients achieving maintenance 
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patients on monotherapy, with an ALT (<50 IU/mL) and a GGTP (<50 IU/mL) at 1 and 2 year follow up. At 1 year 
follow up, 37.1% (537/1448) were on tacrolimus monotherapy with normal allograft function. Sirolimus 
monotherapy with normal allograft function accounted for 2.1% of transplants.  Of patients with 2 year follow up 
data, 46.9% (500/1067) were on tacrolimus monotherapy with normal allograft function. Sirolimus monotherapy 
with normal allograft function accounted for 3.7% (40/1067) of transplants. 
The probability of having biopsy proven acute cellular rejection for the entire cohort was 22% at 3 months, 26.7% 
at 6 months, and 34.7% during the first year after transplant (Figure 7a).  Biopsy proven rejection rates were also 
compared by induction strategy (Figure 7b). Of patients using anti-thymocyte or other lymphocyte induction 
agents (n=93), the probability of rejection by 1 year was 51.5%. For patients receiving IL-2 receptor monoclonal 
antibodies (n=517), the probability of biopsy proven rejection was 35.5% at 1 year, similar to that of the cohort not 
receiving antibody induction (33.4%). After accounting for the ABO incompatible transplants that died early, 
rejection rates by donor-recipient blood group matching (identical, compatible, or incompatible) were not 
statistically different over a 36-month time period (7c).
Growth
Weights were recorded for 1806/1364/970 children at transplant, 1 year and 2 years post-transplant, respectively.  
Over this time period, median weight Z-score increased steadily, from -0.6 to -0.1 to 0.2.  Height/length was 
recorded for 1662/1354/954 children at transplant, 1 year, and 2 years post-transplant. Similarly, median Z-scores 
increased from -1.1 to -0.8 to -0.6 over this time period (Figure 8). 
Discussion
The current SPLIT registry has enrolled nearly 2000 pediatric liver transplant recipients. This volume provides the 
opportunity to characterize the latest cohort of pediatric recipients stratified by demographics, 
immunosuppression, and clinical outcomes.  
Several important trends are identified in the current data set. Of note, the indications for liver transplant have 
changed since the last cohort was described. The percentage of patients transplanted for biliary atresia has 
decreased due to the broader acceptance of liver tumors and metabolic disease as indications for liver transplant 4.  
The registry now follows longitudinal data for over 700 biliary atresia patients and 200 fulminant liver failure 
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As published in other reports, our data support that PELD/MELD exception scores account for a large proportion of 
organ allocation at time of transplant. This percentage has increased to greater than 40% from the previous SRTR 
data rate of 24.3% in the 2004-2006 cohort.9 The fact that this practice has been necessary to achieve liver 
transplant in children will need to be tracked continually in light of the implementation of the pediatric National 
Review Board and the new UNOS allocation schemes.  Although 28.5% of all liver recipients are under 1 year of 
age, there are only 9.1% of donors coming from children < 1 year.  
Living donation still appears to be an important method to achieve transplant in young recipients. Interestingly, 
this cohort also has a high percentage of adolescents that received living donation. We hypothesize that utilization 
of living donors in the adolescent population represents an attempt to address the challenge that adolescents face 
in organ allocation under MELD.
Liver transplantation with an ABO-incompatible graft was performed in over 4% of our cohort, higher than the 
2.2% reported in SRTR reports from a decade ago. 9 This population’s graft and patient survival percentages are 
inferior to other transplants, possibly related to the fact that the majority of these patients are quite small and 
very ill at time of transplant, with close to 80% being either Status 1A/1B or having PELD/MELD ≥ 25. The death 
rate and graft failure rate is highest in the first 30 days.  Interestingly, the rejection rates were similar to 
identical/compatible transplants, so there were probably other underlying factors and comorbid conditions that 
contributed to the inferior graft and patient survival in this population. Further analysis is required as outcomes 
following this practice are captured by the registry. 
The registry continues to reveal the evolution of trends in immunosuppression over the decades, but also 
demonstrates the wide variability in immunosuppression practices among the centers at multiple time points. Still 
close to one-third of transplant centers follow protocols that use antibody induction; Tacrolimus is initiated in 97% 
of transplants; Sirolimus use is increasing, and cyclosporine use is almost non-existent. Interestingly, children 
receiving anti-lymphocyte agents have a higher observed rejection rates in the first year post-transplant in 
comparison to IL-2 monoclonal antibody induction or no antibody induction. The data set is not robust enough to 
assess causality at this time, but may do so in future reviews. 
Quality measures including time to extubation appear quite short. There have been published studies that support 
the active engagement of anesthesiologists in the selection process to promote early extubation, even in the 
operating room. 10  Overall hospital length of stay after transplant for this cohort was around the national OPTN 
data median of 15 days.  Interestingly, despite many centers implementing specific efforts to avoid early re-
admissions to the hospital, almost one-third of patients were re-admitted within 7 days of discharge. This is an 
important factor for payor reimbursement, and could definitely be a future focus for quality initiatives. 
Complications after transplant appear similar to previous reports with re-exploration, vascular and biliary 
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This new SPLIT registry has provided the opportunity to identify and answer new questions, as well as to affirm 
previous ones. The revised SPLIT database continues to be actively utilized as the backbone for newly developed 
ancillary studies; a goal of the new database.  SPLIT generated ancillary studies include graft type outcomes, CMV 
prophylaxis strategies 13, cirrhotic cardiomyopathy, biliary stricture management strategies, and hepatic artery 
thrombosis prevention/management with most currently in manuscript preparation. The registry now provides 
data access through a new web-based QI benchmarking project developed by the SPLIT QI committee. Quality 
initiatives have always been important to SPLIT and may take on a greater role in the future as data driven QI 
efforts to derive best practices receive increased visibility in the pediatric community. 6,14
There a number of factors affecting the effectiveness of the SPLIT registry, including those relevant to registry 
based research and analyses. Some high volume US centers have simply decided not to participate in SPLIT.  
Fortunately, all 3 Canadian sites are participating.  Close to 85% of all US centers averaging over 5 transplants per 
year are participating. Unfortunately, not all children at participating SPLIT centers have been enrolled due to 
various issues. The registry committee is currently attempting further analysis of the reasons for no consent, in 
order to help centers optimize center enrollments moving forward. The lack of full center enrollment may 
introduce selection bias, weakening the power of the registry, especially if enrollment rates are <80% of 
UNOS/Canada reported transplants. Fortunately, over 97% of the data fields captured by SPLIT were complete for 
the patients that are enrolled.  In addition, SPLIT data were quite comparable to that of the SRTR registry in terms 
of diagnosis, demographics, medical condition at transplant, MELD/PELD exception, ABO compatibility, and donor 
type.
In summary, the latest SPLIT registry is now comprised of close to 2000 pediatric patients with their first liver 
transplant. Data continue to be prospectively collected from 39 participating sites in the United States and Canada 
longitudinally. The data set captured is much more granular than other registries permitting analysis of factors 
affecting long-term outcomes in pediatric transplant recipients. The registry now has 5-year data for over 200 
patients. With cooperative data collection from multiple centers, SPLIT remains poised to ask questions that are 
not easily answered by single center reviews. The data captured continue to be used to generate further clinical 
and research hypotheses facilitated by a web-based interactive benchmarking tool.  The data, outlined above, 
provide the backbone for ancillary studies.  The flexibility of the collaborating centers and the data coordinating 
center has permitted the addition of new data elements collected to answer specific queries over specified time 
frames. In addition, the data sets provide for center QI benchmarking that is imperative for transplantation 
practices to evolve into the 21st century. As part of the evolution from a mere registry to a quality improvement, 
research and advocacy collaborative, SPLIT has become a pediatric transplant society. In 2018, maintaining the 
same acronym for continuity purposes, SPLIT has now become the Society of Pediatric Liver Transplantation, an 
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Table 1. Demographics at first liver transplant
Age at transplant (years) Participants (n=1911)
(%)
<1 year 546 (28.6)
1-5 years 733 (38.4)
6-10 years 260 (13.6)






















Black or African American 257 (13.4)
Asian 122 (6.4)
American Indian/Alaska native 19 (1.0)
Native Hawaiian or Other Pacific Islander 9 (0.5)
More than one 59 (3.1)
Other 91 (4.8)
Primary caregiver marital status
Missing 59 (3.1)
Single parent 305 (16.0)
Married 1321 (69.1)
Divorced 76 (4.0)
Domestic partnership 44 (2.3)
Unknown 100 (5.2)
Primary caregiver Highest Level of Education
Missing or unknown 806 (42.2)
Some high school or less 156 (8.2)
High school diploma/GED 291 (15.2)
Vocational school 212 (11.1)
College degree 313 (16.4)
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Table 2. Primary diagnosis at time of transplant
Primary diagnosis N=1911 (%)
Cholestatic 904 (47.3)
Biliary atresia 733 (38.4)
Alagille syndrome 78   (4.1)
TPN induced cholestasis 6     (0.3)
Neonatal hepatitis 15  (0.7)
PFIC 1 12  (0.6)
PFIC2 28  (1.5)
PFIC3 15  (0.7)
Other  biliary/cholestatic  conditions 17  (0.9)
Metabolic Disease 364 (19.0)
Alpha-1 antitrypsin 58 (3.0)
Wilson’s disease 12 (0.6)
Tyrosinemia 5 (0.3)
Primary Hyperoxaluria 11 (0.6)
Cystic Fibrosis 23 (1.2)
Crigler-Najjar 13 (0.7)
Glycogen storage disease 20 (1.0)
Urea cycle disorder 113 (5.9)
Maple Syrup Urine disease 48  (2.5)
Organic acidemia 33 (1.7)
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Niemann Pick C 2 (0.1)
Other metabolic disease 12 (0.6)
Tumor 223 (11.7)
Hepatoblastoma 175 (9.2)
Hepatocellular carcinoma 24  (1.3)
Other tumor 24 (1.3)
Fulminant liver failure 219 (11.5)
Indeterminate 140 (7.3)
Hepatitis A 2    (0.1)
Hepatitis B 1   (0.1)
Hepatitis C 1   (0.1)
Herpes Simplex 2   (0.1)
Other viruses 5   (0.3)
Autoimmune hepatitis 17 (0.9)
Acetaminophen 7   (0.4)
Wilson’s disease 10 (0.5)
Drug induced 10 (0.5)
GALD 7   (0.4)
Hemophagocytic syndrome 4   (0.2)
Other liver failure 13 (0.7)
Cirrhosis 132 (6.9)
Autoimmune hepatitis 35 (1.8)
Primary sclerosing cholangitis 49 (2.6)
Hepatitis B 1 (0.1)
Other cirrhosis 47 (2.5)
Other 61 (3.2)















This article is protected by copyright. All rights reserved
Abernethy  malformation 8 (0.4)
Congenital hepatic fibrosis/Caroli’s 14 (0.7)
Choledochal cyst 10 (0.5)
Other 27 (1.4)
Missing 7 (0.4)









A 469 (87.7%) 7 (3.8%) 4 (13.3%) 117 (11.0%)
B 5 (0.9%) 141 (77.5%) 2 (6.7%) 89 (8.4%)
AB 23 (4.3%) 18 (9.9%) 21 (70.0%) 10 (0.9%)
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Table 4.  Sentinel benchmarking data captured in the registry
Number of transplants
Patient survival at 30 days,90 days, 1 and 2 years
Graft survival at 30 days, 90 days, 1 and 2 years
Rejection at 30 days, 90 days, 1 and 2 years
Percentage of patients with monotherapy, ALT<50, GGT<50  at 30 days, 90 days, 1 and 2 years
Initial hospitalization days
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Figure Legends
Figure 1.  Number of children receiving a first liver transplant in the SPLIT registry
Figure 2. Percent of children transplanted within diagnostic categories
Figure 3. Donor organ type shown for recipient age ranges
Figure 4.  Kaplan-Meier estimate for overall patient and graft survival over time, including the number of patients 
at risk.
Figure 5a. Kaplan-Meier estimate of patient survival over time, by ABO blood type compatibility
Figure 5b. Kaplan-Meier estimate of graft survival over time, by ABO blood type compatibility
Figure 6. Use of immunosuppression from time of transplant to 12 months after transplant
Figure 7a. Kaplan-Meier estimate of acute cellular rejection over time for the entire registry
Figure 7b.  Kaplan-Meier estimate of acute cellular rejection over time by induction strategy. Anti-thymocyte 
globulin (ATG), IL-2 monoclonal antibody (IL-2mAb). 
Figure 7c. Kaplan-Meier estimate of acute cellular rejection over time, by ABO blood type compatibility
Figure 8.  Weight and height Z scores at transplant, 1 and 2 years post-transplant.
The SPLIT research group is composed of the following centers, investigators and coordinators. Alfred I duPont 
Hospital (S. Dunn, A. Martin, D. Mannino, L. Flynn), Ann & Robert Lurie Children’s Hospital of Chicago (S. 
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Zapata), Cardinal Glennon Children’s Hospital, St. Louis University ( A. Jain, E. Foristal), Children’s Healthcare of 
Atlanta (N. Gupta), Children’s Hospital Cincinnati (J. Bucuvalas, A. Hawkins, J. Hardy, E. Engels, A. Schreibeis ), 
Children’s Hospital at Montefiore (N.  Ovchinsky, D. Kogan-Liberman, J. Ricciardi, S. Thomas, R. Cunningham, P. 
Malik),  Children’s Hospital Colorado (S. Sundaram, A. Feldman, M. Hite, E. Palmeri), Children’s Hospital of Los 
Angeles (R. Kohli, J. Emamaullee, C. Secules), Children’s Hospital of Michigan ( J. Magee, J. Lopez, J. Bilhartz, J. 
Hollenbeck, B. Shaw,  C. Bartow, S. Forest); Children’s Hospital of Philadelphia (E. Rand, A. Byrne, I. Linguiti, L. 
Wann, C. Seidman); Children’s Hospital of Pittsburgh (G. Mazariegos, K. Soltys, J. Squires, A. Rzempoluch); 
Children’s Hospital of Wisconsin (B. Vitola, G. Telega, S. Lerret); Children’s Medical Center of Dallas, Dallas TX (D. 
Desai, J. Moghe, L. Cutright); Children’s Mercy Hospital, Kansas City, MO (J. Daniel, W. Andrews, V. Fioravanti, V. 
Slowik, R. Cisneros, M. Faseler, M. Hufferd); Duke University Medical Center (D. Sudan, A. Mavis, L. Moats, S. Swan-
Nesbit); Georgetown University (N. Yazigi, A. Buranych, A. Hobby); Indiana University Medical Center (G. Subbarao, 
B. Maccaby); Levine Children’s Hospital, Charlotte, NC (V. Gopalareddy, M. Boulware); Mayo Clinic, Rochester, MN 
(M. El Youssef, K. Furuya, S. Ibrahim, A. Schatz, J. Weckwerth); Medical University of South Carolina ( N. Kasi, S. 
Nadig). Mount Sinai Medical Center, New York, NY (R. Arnon, J. Chu, M. Czurda, B. Secheli, C. Almy, B. Haydel); 
New York Presbyterian Hospital, New York, NY (S. Lobritto, J. Emand, P. Reddy, C. Falo, E. Biney-Amissah, A. 
Gomez, A. Repp); Ochsner Medical Center, New Orleans, LA (J. Seal, S. Stewart, J. Bergeron, A. Truxillo); Phoenix 
Children’s Hospital, Phoenix, AZ (S. Lebel, H. Davidson); Primary Children’s Hospital, Salt Lake City, UT (L. Book, D. 
Ramstack, A. Riley, C. Jennings); Seattle Children’s Hospital, Seattle, WA (S. Horslen, E. Hsu, K. Wallace); St. Louis 
Children’s Hospital, St. Louis, MO (Y. Turmelle, M. Nadler, S. Postma); Texas Children’s Hospital, Houston, TX (T. 
Miloh, R. Himes, J. Economides, K. Timmons); The Hospital for Sick Children, Toronto (V. Ng, A. Subramonian). 
UCLA Medical Center, Los Angeles, CA (S. McDiarmid, S. Feist); UCSF Benioff Children’s Hospital, San Francisco, CA 
(S. Rhee, E. Perito, L. Gallagher, K. Smith, N. Ebel, M. Zerofsky), University of Alabama, Birmingham (J. Nogueira), 
University of Alberta, Edmonton (S. Gilmour, C. Robert, C. Cars); University of Chicago (R. Azzam, P. Boone); 
University of North Carolina at Chapel Hill (N. Garbarino,  M. Lalonde ); University of Rochester, Rochester, NY (N. 
Kerkar, K. Helbig, K. Dokus, C. Doane, J. Cocking, T. Schieber); Vanderbilt Children’s Hospital, Nashville, TN (S. 
Alexopoulos, C. Bhave, R. Schillo, A. Bailey, D. Dulek, L. Ramsey); Yale New Haven Children’s Hospital, New Haven, 
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